Supporting Self-Management of Healthy Behaviors in Diabetes, Kidney Disease, and Hypertension

June 10, 2026 updated by: University of Pennsylvania

Supporting Self-Management of Healthy Behaviors Among People With Diabetes, Kidney Disease, and Hypertension (SMART-HABITS-4-Health): A Pilot Trial of a Blood Pressure Monitoring Intervention Leveraging Social Incentives and Gamification

The planned intervention, entitled, Supporting Self-Management of Health Behaviors to Optimize Health (SMART-HABITS for Health), aims to provide support for patients with chronic kidney disease (CKD), hypertension and diabetes by providing text messages delivered as motivational reminders and support to encourage blood pressure self-monitoring through goal setting, customized task prompts via text message and feedback, leveraging social connections, and use of a gamification design.

Study Overview

Detailed Description

The pilot trial is designed to study the feasibility of a smartphone-based behavioral intervention in a two groups of participants diagnosed with chronic kidney disease (CKD), diabetes, and hypertension. The patients will be identified for eligibility by screening the scheduled for follow up appointments in the Penn renal CKD clinics. Patients will be prospectively enrolled after informed consent. Participants will be prospectively enrolled and will be randomized to participate into one of two arms.

  • Arm 1: Social Support - the participant's performance shared with an identified personal support person, such as a friend or a family member or a Peer Mentor; the support person is encouraged to support the participant on at least a weekly basis. Prior to randomization, each participant will select their preference of a personal support personal or a Peer Mentor. A Peer Mentor is a person also with CKD, HTN, and diabetes who has successfully incorporated regular blood pressure monitoring into their lives.
  • Arm 2: Social norms -Participants will have access to a leaderboard of all people in the study that shows blood pressure performance information (frequency and control). They will also receive weekly feedback regarding their personal blood pressure performance, compare to their individualized goals and from the preceding week.

All participants will receive text message reminders sent to prompt blood pressure self-monitoring at least 5 times per week, transmit the blood pressure readings to the secure Way to Health server via Omron Connect app. If a blood pressure reading is not received within 5 hours, another reminder will be sent. Automated text message feedback will be sent after the blood pressur reading is recorded with a tailored message regarding any further required actions based upon the BP readings obtained. Any participant with a single systolic blood pressure reading 200mmHg or two consecutive systolic blood pressure readings 180 mmHg or diastolic blood pressure readings 110 mmHg will be contacted immediately by an MD (Dr. Schrauben) for assessment (including evaluation for symptoms of hypertensive emergency) and referral to the emergency department, if indicated. Please see full text message algorithm (attached protocol). Any participant will undergo re-engagement protocol for low participation.

To further support behavior engagement, there is a gamification element to the design:

  • At the beginning of each week (Monday), all participants will receive 70 points (10 points for each day of the week). If participants do not send a BP each day, they will lose 10 points. The goal is to check blood pressure at least 4 days per week.
  • All participants will start the study at the second of five levels. At week's end (Sunday), if a participant has ≥40 points, their average systolic blood pressure was in their individualized controlled goal, or their average BP declined from the week prior, they will move up a level to acknowledge goal attainment and improvement, and if not, they will drop a level.
  • If a participant reaches the 4th level out of five, they will receive a digital trophy. At study's end, if they accumulate ≥5 trophies, they will receive a mug.
  • If a participant reaches the 5th level, they will receive a digital medal. At study's end, if they accumulate ≥4 medals, they will receive a tote bag.
  • Each week, participants will receive 50 points to leverage "fresh-start effect"

At the end of the study, each participant will be invited to participate in focus groups for additional feedback on their experience.

Study Type

Interventional

Enrollment (Actual)

73

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Penn Presbyterian Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • diagnosis of chronic kidney disease (any stage), hypertension, diabetes
  • followed at University of Pennsylvania nephrology practice
  • aged 18 years or over. -
  • own a smart device (smartphone or tablet) capable of connecting to the internet and has Bluetooth enabled technology
  • able to comprehend English.
  • a mean blood pressure reading of <180/100 mmHg in person study visit
  • able and willing to provide informed consent

Exclusion Criteria:

  • inability to provide consent or read or speak English
  • inability to self-monitor (e.g., diagnosis of dementia, cognitive impairment, physically unable to set up BP cuff and machine)
  • already participating in another blood pressure study or intervention trial
  • vulnerable populations, living in a long-term care or rehabilitation institution,
  • if likely to have their care transferred to another facility outside participating clinic areas during the course of the study
  • planning to travel or live consecutively out of the country for more than one month
  • mean blood pressure reading of >180/100 mmHg at in person study visit
  • hypertension not managed by the nephrologist in Penn Medicine
  • any other reason they do not expect to be able to complete the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Support Person
A support person not in the study will receive the participant's weekly blood pressure performance details and will contact them at least on a weekly basis to encourage continued blood pressure monitoring. Prior to randomization, the participant will select a preference between a support person that is close to them (e.g., friend or family member) or a support person who is provided by the study, a Peer Mentor.

Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.

This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly.

Other Names:
  • Social Support
  • Peer Mentor
Experimental: Social Norms
In this arm, participants will be texted reports of blood pressure performance statistics of the other participants in the study and also receive weekly feedback about how their blood pressure information compares to others in the study. Participants in this arm will have access to a leaderboard that displays this information.
Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
Other Names:
  • comparative information
  • normative feedback

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility: Adoption
Time Frame: Collected throughout study (8 weeks)
Composite outcome determined by participant retention rate, total number of assessments performed by participants over complete study period; Good adoption will be determined by greater than or equal to 70 percent of those retained in the study, and greater than or equal to 70 percent of those enrolled who actually used SMART-HABITS-4-Health at least one time as measured by data usage statistics.
Collected throughout study (8 weeks)
Feasibility: Adherence - Number of Participants Completed 70% or More Blood Pressure Measurements
Time Frame: Collected throughout study (8 weeks)
Participants reported represent participants with good adherence, which was determined by 70% or more of the blood pressure assessments throughout the study period out of the recommended.
Collected throughout study (8 weeks)
Feasibility: Acceptability of SMART-HABITS-4-Health
Time Frame: collected at 4 weeks
Determined through satisfactory score on the System Usability Scale survey (defined as a score above 68). Survey range is 0-100, with higher scores indicating more usability and acceptability.
collected at 4 weeks
Feasibility: Acceptability of SMART-HABITS-4-Health
Time Frame: collected at 8 weeks
Determined by satisfactory score on the System Usability Scale (SUS) survey (defined by a score above 68). The SUS score range is 0-100, with higher scores indicating better usability and acceptability.
collected at 8 weeks
Feasibility: Acceptability of SMART-HABITS-4-Health
Time Frame: Collected within 12 weeks of study completion
Determined by inductive qualitative analysis from semi-structured interviews with study participants after the end of the pilot study. There is no a priori set up codes or scales to assess this outcome as it is purely a qualitative outcome.
Collected within 12 weeks of study completion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CKD Knowledge
Time Frame: 8 weeks
Determined by change in enrollment survey and end of study survey scores on responses regarding CKD knowledge using the 28-question Kidney Knowledge Survey (KiKS). The survey score is defined as the sum of the correct responses to each survey question divided by the total number of questions, total score range (0-1). Higher scores indicate better knowledge.
8 weeks
Maintenance
Time Frame: 8 weeks
Determined by the usage of SMART-HABITS-4-Health. Good maintenance will be determined by at least one access to the SMART-HABITS-4-Health portal or one BP monitor each week.
8 weeks
Social Incentive Effectiveness
Time Frame: 8 weeks
Mean change in baseline blood pressure (the baseline visit BP) to mean blood pressure after 8 weeks in both arms.
8 weeks
Self-Efficacy
Time Frame: 8 weeks
Determined by change in enrollment survey and end of study survey scores on responses regarding self-efficacy using the Self-Efficacy for Managing Chronic Disease 6-Item Scale. Answers range from 1 = not at all confident to 10= totally confident. Total summary score range is 6-60, with higher summary scores indicating higher self-efficacy.
8 weeks
Chronic Disease Self-Management
Time Frame: 8 weeks
Determined by change in enrollment survey and end of study survey scores on responses regarding self-management using the Partners in Health Scale for Chronic Condition Self-Management (11 items). Answers range from 0=very good to 8= very poor for each of the 11 items. Total summary score range is 0-88, with higher summary scores indicating better self-management.
8 weeks
Disease Related Quality of Life Change Scores
Time Frame: 8 weeks
Change from baseline to end of study in disease-specific quality of life as measured by the Kidney Disease and Quality of Life 36-item survey (KDQOL-36), a validated instrument assessing health-related quality of life in individuals with kidney disease. The KDQOL-36 includes kidney disease-specific sub scales: Burden of Kidney Disease, Symptoms and Problems, and Effects of Kidney disease on Daily Life. Raw scores are transformed to T-scores, standardized to a general population reference with a mean of 50 and standard deviation of 10. For all sub-scales, higher T-scores indicate better health-related quality of life (i.e., lower symptom burden and less impact of kidney disease), while lower scores indicate worse quality of life. Scores are reported separately by each domain. A change of approximately 5 points is generally considered clinically meaningful in kidney disease populations.
8 weeks
Reach
Time Frame: 8 weeks
Determined by the comparison of the sex frequency (percentage) of the enrolled participants compared to sex frequency of general population with chronic kidney disease, diabetes, and with hypertension in the United States (approximately 54% female and 46% male).
8 weeks
Reach
Time Frame: 8 weeks
Determined by the comparison of race groups (Black, White Asian, other) frequency (percentage) of the enrolled participants compared to the race frequencies of the general population with chronic kidney disease, diabetes, and with hypertension in the United States (approximately 20% for Black, 12% White, 14% Asian, and 14% Hispanic).
8 weeks
Implementation Issues
Time Frame: 8 weeks
Qualitative reports describing adaptions that were made to the SMART-HABITS program in response to participant feedback, including descriptions of alterations that were made to the schedule of reminders and messaging content. Participant feedback data collected with field notes from verbal conversations and textual data from email and text messages.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sarah Schrauben, MD, MSCE, University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 21, 2023

Primary Completion (Actual)

January 31, 2025

Study Completion (Actual)

March 31, 2025

Study Registration Dates

First Submitted

July 5, 2022

First Submitted That Met QC Criteria

September 29, 2022

First Posted (Actual)

October 4, 2022

Study Record Updates

Last Update Posted (Actual)

July 8, 2026

Last Update Submitted That Met QC Criteria

June 10, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Support Person

3
Subscribe